Glycogen storage disease type II secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
Line 54: | Line 54: | ||
| style="background:#DCDCDC;" + |<small>'''Adopted from Genetics in Medicine'''</small> | | style="background:#DCDCDC;" + |<small>'''Adopted from Genetics in Medicine'''</small> | ||
|- | |- | ||
| | |||
===Gastrointestinal/nutritional recommandations=== | ===Gastrointestinal/nutritional recommandations=== | ||
|- | |- | ||
| | | style="background:#F5F5F5;" + | | ||
*Obtain videofluoroscopic swallowing assessment and evaluation for GE reflux to guide management of feeding (oral/gavage feeding) at baseline and as clinically indicated. | *Obtain videofluoroscopic swallowing assessment and evaluation for GE reflux to guide management of feeding (oral/gavage feeding) at baseline and as clinically indicated. | ||
*Provide oral stimulation and non-nutritive sucking for infants who are nonoral feeders. | *Provide oral stimulation and non-nutritive sucking for infants who are nonoral feeders. |
Revision as of 20:17, 16 January 2018
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II secondary prevention On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II secondary prevention |
FDA on Glycogen storage disease type II secondary prevention |
CDC on Glycogen storage disease type II secondary prevention |
Glycogen storage disease type II secondary prevention in the news |
Blogs on Glycogen storage disease type II secondary prevention |
Directions to Hospitals Treating Glycogen storage disease type II |
Risk calculators and risk factors for Glycogen storage disease type II secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Secondary Prevention
- Effective measures for the secondary prevention of glycogen storage disease type 2 (GSD type 2) include:[1]
- General medical care recommendations
- Cardiology recommendations
- Pulmonary recommendations
- Gastrointestinal/nutritional recommandations
- Musculoskeletal/functional/rehabilitation recommendation
- Neurological recommendations
General medical care recommendations |
|
Adopted from Genetics in Medicine |
Cardiology recommendations |
|
Adopted from Genetics in Medicine |
Pulmonary recommendations |
|
Adopted from Genetics in Medicine |
Gastrointestinal/nutritional recommandations |
|
Adopted from Genetics in Medicine |
Musculoskeletal/functional/rehabilitation recommendation |
|
Adopted from Genetics in Medicine |
Neurological recommendations |
|
Adopted from Genetics in Medicine |
Surgery/Anesthesia recommendations |
|
Adopted from Genetics in Medicine |
References
- ↑ ACMG Work Group on Management of Pompe Disease. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ; et al. (2006). "Pompe disease diagnosis and management guideline". Genet Med. 8 (5): 267–88. doi:10.109701.gim.0000218152.87434.f3 Check
|doi=
value (help). PMC 3110959. PMID 16702877.